PATENT CLAIM ANALYSIS

Application Number: 15942802
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["514", "230500"]

Abstract:
The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg/mL to 85 pg/mL.

Claim (Index 3):
A Selective Progesterone Receptor Modulator (SPRM) namely (11\u03b2,17\u03b2)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one (Compound 1) of formula (I) or a stereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same wherein the Compound 1 is administered to women in need of treatment as detailed below in a daily dosage of 1 mg to 5 mg during a treatment period of four (4) weeks to one (1) year; for use in the treatment and/or prophylaxis of a sexual hormone dependent disease and gynaecological diseases, preferably, the disease is selected from Endometriosis, Uterine Fibroids (UF) and associated symptoms thereof; wherein women in need of treatment are diagnostized as developing estrogen-depletion associated with physiological changes or are potentially at risk of estrogen-depletion associated with physiological changes selected from vulvar and vaginal atrophy causing vaginal dryness, pruritus and dyspareunia, and vasomotor instability manifested as hot flushes and loss of bone mineral density when treated with Selective Progesterone Receptor Modulator (SPRM) such as but not limited to Ulipristal acetate (UPA) or Gonadotrophin-Releasing Hormone (GnRH) analogues such as but not limited to Leuprolide and Elagolix with the proviso that SPRM is not defined as Compound 1.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.33846
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13855559', '12990203', '14440023', '14251192', '12446567']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7942811388602898
- 35 USC 102 Novelty (BERT): 0.5291559095049739
- Combined Prediction Score: 0.7677686159247582
- Mean Citation Score: 317.07148400000005
- Max Citation Score: 345.38397000000015
- Similarity Product: 242.27262919713385

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test